Skip to textbook content
Doctor’s PassportTextbook
QuestionsFlashcardsBriefsDashboardAccount
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Intrahepatic cholestasis of pregnancy

Obstetrics and gynaecology · UK scope · Sources checked 7 Sept 2026 · Clinical review pending

RapidFull
!
Reduced movements or systemic illness

In a pregnancy affected by cholestasis, reduced fetal movements need immediate maternity assessment; severe abdominal pain, vomiting, jaundice or confusion may indicate another hepatic emergency.

Action: Contact maternity triage immediately for reduced movements or acute maternal illness, assess maternal observations and fetal wellbeing, and obtain urgent liver, renal, glucose and coagulation tests when systemic features are present.

Synopsis

Assess pregnancy-related itch using bile acids and competing diagnoses, then individualise symptom relief, surveillance and birth timing according to fetal risk.

  • Suspect intrahepatic cholestasis when pregnancy itch occurs without a primary skin eruption, often affecting palms and soles.
  • Measure total bile acids and liver enzymes; persistent symptoms warrant repeat testing even when initial results are normal.
  • RCOG defines mild disease by peak bile acids 19–39 micromol/L, moderate by 40–99 and severe by 100 or more.
  • Use the highest relevant bile acid concentration and the complete pregnancy history when discussing risk and timing of birth.
  • Ursodeoxycholic acid can offer limited itch relief; it is not proven to prevent stillbirth and cannot replace a birth plan.
  • Confirm symptom and biochemical resolution after birth, and investigate persistent abnormalities rather than assuming they remain pregnancy-related.

Key red flags

Reduced or altered fetal movements require prompt maternity assessment even when recent bile acids or fetal checks were reassuring.

Jaundice with vomiting, right upper quadrant pain, bleeding, hypoglycaemia or altered consciousness is atypical for straightforward cholestasis and requires urgent hospital investigation.

Bile acids reaching 100 micromol/L or above require specialist review of the planned birth date and coexisting risk factors.

Investigation priorities

01
Total serum bile acidsFirst step

Confirm biochemical cholestasis and stratify pregnancy risk using RCOG categories.

Management branches

Diagnostic assessmentInvestigate persistent pregnancy itch

A pregnant patient reports new itch without a convincing primary dermatological cause.

  1. Request bile acids and liver tests, document the skin findings and review medications, previous liver disease and associated obstetric symptoms.
  2. Arrange repeat testing if symptoms persist despite normal results, with earlier review if jaundice, pain or systemic illness develops.
  3. Refer confirmed or atypical disease to obstetric care and expand the liver work-up when the clinical pattern does not fit isolated ICP.

Key medicines

Ursodeoxycholic acidA UK trial regimen started at 500 mg orally twice daily, with clinician titration according to response; prescribe and stop after birth through the obstetric plan.Do not present the PITCHES regimen as a licensed ICP dose or claim it prevents stillbirth; review diarrhoea, interactions and the specific product information.
Bland emollientApply an unperfumed emollient to itchy skin as needed throughout the day, reducing or changing the product if irritation occurs.Keep emollient-contaminated clothing and bedding away from flames; worsening itch still requires the planned clinical and biochemical reassessment.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 7 Sept 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 7 Sept 2026; clinical approval remains outstanding.

  • RCOG GTG43 intrahepatic cholestasis categories
  • RCOG intrahepatic cholestasis patient information
  • PITCHES randomised trial protocol and clinical findings
  • Ursofalk 500 mg tablets UK SmPC
  • EASL clinical practice guidance on liver disease in pregnancy

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom